RBC Looks For Post-Approval Data On MannKind
Shares of MannKind (NASDAQ: MNKD) have traded up as much as 11 percent Monday, following Friday's announcement by the company that AFREZZA has received FDA approval.
In response to the announcement, RBC Capital released a note stating that the next key catalysts the firm sees are post-approval data and a partnership, which the firm views as "likely."
Shares of Mannking are currently trading at $11.01, up 10.1 percent.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.